In a development that could significantly improve blood product availability for hospitals across the United States, researchers have demonstrated that platelets can be safely refrigerated for up to three weeks without losing their ability to stop bleeding. The findings, published in JAMA, suggest a three‑fold increase in the usable platelet supply and a major reduction in waste.
Refrigerated platelets perform as well as room‑temperature units
The study involved 1,000 patients—both children and adults—undergoing cardiac surgery at 27 hospitals in the United States and Australia. Participants received either standard room‑temperature platelets, which must be used within five to seven days, or platelets that had been stored at 4°C for up to three weeks. Outcomes showed no difference in bleeding control between the two groups.
Each year, U.S. hospitals collect roughly 2.5 million room‑temperature platelet units, many of which are discarded because of the short shelf life. Dr. Philip Spinella, the study’s lead author from the University of Pittsburgh, said the new storage method “will dramatically improve the availability of platelets while also reducing waste, allowing hospitals that aren’t in major cities to afford to keep this life‑saving blood product on hand for bleeding patients.”
Implications for rural and community hospitals
Rural and smaller community hospitals often cannot justify maintaining a stock of room‑temperature platelets, as they treat fewer severely bleeding cases. Extending platelet viability to three weeks could enable these facilities to keep a ready supply, improving emergency care for patients who might otherwise need to be transferred to larger centers.
The researchers noted that the data are currently under review by the U.S. Food and Drug Administration and comparable regulators abroad. If approved, the change could reshape blood‑bank logistics nationwide.
Airline crews face elevated radiation‑related cancer risk
In a separate health‑related analysis, researchers examined death‑certificate data from the National Vital Statistics System covering 2020‑2024. The study, also appearing in a JAMA journal, found that U.S. pilots and flight attendants experience higher rates of death from radiation‑related cancers—including breast, central‑nervous‑system, prostate cancers and melanoma—than workers in other occupations.
Approximately 6.9 % of flight‑attendant deaths and 6.7 % of pilot deaths were linked to radiation‑related cancers, compared with lower rates among nuclear‑medicine technologists, who also encounter occupational radiation. Pilots additionally showed a higher rate of leukemia deaths.
Flight crews accrue an estimated 3 to 6 millisieverts of cosmic radiation per year, far exceeding the 0.4 millisieverts received by a typical air traveler who makes ten cross‑country round‑trip flights annually. Although the Federal Aviation Administration recognizes airline crews as occupationally exposed to ionizing radiation, they are not subject to the same federal dose limits or monitoring requirements that apply to other radiation‑exposed workers in the United States.
Calls for policy attention
Commentators not involved in the study urged policymakers, regulators, airlines, and clinicians to take the findings seriously. An accompanying editorial recommended that physicians maintain a heightened index of suspicion when evaluating airline personnel with symptoms that could indicate cancer.
Both studies underscore how advances in medical practice and awareness of occupational hazards can directly affect the health and safety of everyday Americans, from patients in small‑town hospitals to the men and women who keep the nation’s skies moving.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
